Indivumed and University of Rochester Team Up for Cancer Research

Indivumed and the University of Rochester Medical Center (URMC) have announced an expanded collaboration aimed at developing innovative cancer therapeutics. This partnership will enhance precision oncology efforts by combining Indivumed’s advanced data collection methods with URMC’s expertise in cancer research.

The collaboration was officially announced on December 10, 2025, and focuses on creating patient-centric solutions for various cancers, particularly those at advanced stages. These include colorectal cancer, pancreatic cancer, lung cancer, and breast cancer, with possibilities for future expansion into other cancer types.

Leveraging Expertise for Patient-Centric Research

Indivumed is recognized for its systematic approach to the collection of surgical tissue samples and clinical data, which plays a vital role in cancer research and drug development. Their innovative platform enables the development of well-characterized, patient-derived tumor models (PDTMs) that utilize high-quality biosamples and comply with strict standard operating procedures.

By minimizing ischemia time to under ten minutes, Indivumed ensures that the integrity and quality of the samples collected are maintained. The collaboration with URMC will enhance this process, allowing researchers to utilize advanced cell models, including classical cultures, spheroids, and organoids. These models will be crucial for identifying and validating new pharmaceutical targets in cancer treatment.

Hartmut “Hucky” Land, PhD, Deputy Director of the Wilmot Cancer Institute, expressed enthusiasm about the partnership, stating, “Our previous successful collaborations with Indivumed provide an excellent foundation for this new project. We aim to uncover new therapeutics and biomarkers that will ultimately improve cancer care.”

Building on Previous Successes

This new agreement builds on earlier joint research initiatives, including a recent publication that identified an alternative classification for distinct types of colon cancer. Such insights are expected to significantly augment Indivumed’s ongoing research and development efforts, providing important guidance to clinicians in their therapeutic decision-making processes.

Hartmut Juhl, CEO and founder of Indivumed, commented on the collaboration’s potential, saying, “We are thrilled to deepen our collaboration with URMC, significantly enhancing our ability to identify novel cancer therapeutics in a truly patient-centered approach.” Juhl emphasized the importance of developing primary tumor models to test new compounds against targets identified through Indivumed’s AI-powered data analytics.

With this partnership, URMC joins the Indivumed Global Clinical Network, which includes numerous prestigious hospitals and oncology institutes across North America, Europe, and Asia. The collaboration is set to advance the identification and development of novel cancer therapies, ensuring that patients receive the most effective treatments available.

About the Collaboration Partners

The Wilmot Cancer Institute at the University of Rochester is an NCI-Designated Cancer Center that serves over three million people across 27 counties in Western and Central New York. It is a leader in cancer care and research, providing specialized services through a network of locations, including an 88-bed hospital on the University campus.

Indivumed, a biotech company focused on precision oncology, is dedicated to identifying and developing novel therapeutic targets for cancer treatments. With over twenty years of experience, Indivumed aims to redefine oncology by ensuring that every cancer patient can benefit from precise therapeutic options.

As this collaboration unfolds, both organizations are poised to make significant contributions to the field of cancer research, ultimately aiming to bring new hope to patients facing challenging diagnoses.